ClinVar Miner

Submissions for variant NM_020975.6(RET):c.1901G>T (p.Cys634Phe)

dbSNP: rs75996173
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 7
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV000471652 SCV000543841 pathogenic Multiple endocrine neoplasia, type 2 2023-10-31 criteria provided, single submitter clinical testing This sequence change replaces cysteine, which is neutral and slightly polar, with phenylalanine, which is neutral and non-polar, at codon 634 of the RET protein (p.Cys634Phe). This variant is present in population databases (rs75996173, gnomAD 0.007%). This missense change has been observed in individuals with multiple endocrine neoplasia type 2A (MEN2A), medullary thyroid cancer (MTC) and/or pheochromocytoma (PMID: 8099202, 12000816, 16865647, 17895320, 18062802, 20739875, 24684035, 24716929, 25440022, 25628771). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 13911). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. This variant disrupts the p.Cys634 amino acid residue in RET. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 8099202, 12000816, 21765987, 25440022). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic.
Institute for Clinical Genetics, University Hospital TU Dresden, University Hospital TU Dresden RCV003237413 SCV002011457 pathogenic not provided 2021-11-03 criteria provided, single submitter clinical testing
Ambry Genetics RCV002408463 SCV002718170 pathogenic Hereditary cancer-predisposing syndrome 2017-09-28 criteria provided, single submitter clinical testing The p.C634F pathogenic mutation (also known as c.1901G>T), located in coding exon 11 of the RET gene, results from a G to T substitution at nucleotide position 1901. The cysteine at codon 634 is replaced by phenylalanine, an amino acid with highly dissimilar properties. This mutation has been identified in multiple individuals meeting clinical diagnostic criteria for multiple endocrine neoplasia type 2A (MEN2A) and has been demonstrated to segregate with disease within several MEN2A families (Saito T et al. Am J Med Sci. 2010 Oct;340(4):329-31; Jesic M et al. Srp Arh Celok Lek. 2014 Jan-Feb;142(1-2):72-4; Masbi H et al. Asian Pac J Cancer Prev. 2014;15(5):2027-33; Pandit R et al. Eur. J. Endocrinol. 2016 Oct;175:311-23). This mutation occurs at a known hotspot and studies evaluating genotype-phenotype correlation suggest higher penetrance for pheochromocytoma in MEN2 patients with mutations at amino acid position 634 (Neumann HP et al. N. Engl. J. Med. 2002; 346:1459-66, Quayle FJ et al. Surgery 2007;142:800-5; Yip L et al. Arch Surg 2003; 138:409-16). Per the American Thyroid Association Guideline Taskforce of 2009 (ATA), this mutation has screening and prophylactic recommended interventions beginning in early childhood. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation.
KCCC/NGS Laboratory, Kuwait Cancer Control Center RCV000014928 SCV003927262 pathogenic Multiple endocrine neoplasia, type 2a 2023-05-31 criteria provided, single submitter clinical testing phenylalanine, which is neutral and non-polar, at codon 634 of the RET protein (p.Cys634Phe). This variant is present in population databases (rs75996173, gnomAD 0.007%). This misscnse change has been observed in individuals with multiple endocrine neoplasia type 2A (MEN2A), medullary thyroid cancer (MTC) and7or phcochromocytoma (PMID: 8099202, 12000816, 16865647, 17895320, 18062802, 20739875, 24684035, 24716929, 25440022, 25628771). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 13911). Algorithms developed to predict the effect of misscnse changes on protein structure and function are either unavailable or do not agree on the potential impact of this misscnse change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class CO"). This variant disrupts the p.Cys634 amino acid residue in RET. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 8099202, 12000816, 21765987, 25440022). For these reasons, this variant has been classified as Pathogenic. Pathogenic/likely pathogenic mutations in the RET gene are associated with multiple endocrine neoplasia type 2.
OMIM RCV000014928 SCV000035184 pathogenic Multiple endocrine neoplasia, type 2a 2002-05-09 no assertion criteria provided literature only
OMIM RCV000014929 SCV000035185 pathogenic Familial medullary thyroid carcinoma 2002-05-09 no assertion criteria provided literature only
OMIM RCV000014930 SCV000035186 pathogenic Pheochromocytoma 2002-05-09 no assertion criteria provided literature only

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.